The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | DETERMINATION: results & implications in clinical practice
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, comments on the results of the Phase III DETERMINATION study (NCT01208662) evaluating the use of lenalidomide, bortezomib, and dexamethasone (RVD) versus high-dose melphalan-based conditioning with autologous hematopoietic stem cell transplantation (autoHSCT) in patients with newly diagnosed multiple myeloma (NDMM), discussing progression-free survival (PFS) and overall survival (OS), and the implications of these findings in clinical decision-making. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research Funding: Amgen, Takeda, Sanofi; Speaker’s Bureau, Advisory Boards: Amgen, Takeda, Celgene-BMS, Janssen, Sanofi, Seattle Genetics
